[JUPITER study about rosuvastatin and risk of cardiovascular disease. Unclear consequences for the guideline].
作者信息
Lubsen Jacobus
机构信息
Klinische Epidemiologie, Vufflens-le-Château, Zwitserland.
出版信息
Ned Tijdschr Geneeskd. 2009 Feb 7;153(6):216-7.
PMID:19271438
Abstract
摘要
相似文献
1
[JUPITER study about rosuvastatin and risk of cardiovascular disease. Unclear consequences for the guideline].
Ned Tijdschr Geneeskd. 2009 Feb 7;153(6):216-7.
2
[JUPITER study (2). For now no reason to give statins to more people].
Ned Tijdschr Geneeskd. 2009 Feb 7;153(6):218-9.
3
Cost-effectiveness of rosuvastatin for primary prevention of cardiovascular events according to Framingham Risk Score in patients with elevated C-reactive protein.
J Am Osteopath Assoc. 2010 Aug;110(8):427-36.
4
[JUPITER no support of changed guidelines for cardiovascular prevention. Moderate absolute risk reduction and uncertain long term effects].
Lakartidningen. 2009;106(21-22):1460-1.
5
[The JUPITER study].
G Ital Cardiol (Rome). 2009 May;10(5):267-70.
6
[Less vascular risk with rosuvastatin in elevated CRP].
Ned Tijdschr Geneeskd. 2009 Feb 7;153(6):245.
7
JUPITER study highlights value of anti-inflammatory action of rosuvastatin.
Cardiovasc J Afr. 2009 May-Jun;20(3):211.
8
Rosuvastatin in patients with elevated C-reactive protein.
N Engl J Med. 2009 Mar 5;360(10):1038; author reply 1041-2. doi: 10.1056/NEJMc082574.
9
Low-risk older patients (50 years and older) with raised high-sensitivity CRP (hs-CRP) benefit from rosuvastatin therapy: the JUPITER study.
Cardiovasc J Afr. 2008 Nov-Dec;19(6):332-4, discussion 335.
10
Cost-effectiveness of statin therapy for vascular event prevention in adults with elevated C-reactive protein: implications of JUPITER.
Curr Med Res Opin. 2010 Oct;26(10):2485-97. doi: 10.1185/03007995.2010.516994.
Zotero 插件